Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 24, 2023 7:25am
177 Views
Post# 35358044

RE:RE:RE:RE:RE:RE:SP

RE:RE:RE:RE:RE:RE:SPEach study that was listed was using pelareorep as a monotherapy.

What was discovered was that neither pelareorep or PD-(L)1 immune checkpoint inhibitors work well as a single agent monotherapy.

What also was discovered was that pelareorep + PD-(L)1 immune checkpoint inhibitors when combined were synergistic and that the 2 agents together worked better than either alone. 

How many times does tthat need to be posted before you begin to understand?

What also has been discovered is thst pelareorep and immune checkpoint inhibitors work in certain cancers better than others. How many times does that need to be posted?

And what has been discovered is that the immune system is primed by pelareorep when pelareorep is administered in advance of a PD-(L)1 immune checkpoint inhibitor. This was discovered through the various clinical trials with pelareorep that are listed.

And what has been further discovered is that pelareorep can remodel the tumor microenvironment (TME) from hypoxic to one conducive to checkpoint inhibition. Once again found through the process of scientific discovery.

Also recently discovered through the clinical trial process was that the I/O combination of pelareorep + PD-L1 immune checkpoint inhibitors was effective in pancreatic cancer -  with early results showing a complete response and stable disease responses.

And what pelareorep's scientific journey of discovery has brought us to is the point where 2 Phase 3 studies could bring 2 accelerated approvals with them.

And how many more times does this have to be posted?




<< Previous
Bullboard Posts
Next >>